NEW DIRECTIONAL CALL PLAYS

Cepheid - CPHD - close: 55.69 change: +1.26

Stop Loss: 53.95
Target(s): To Be Determined
Current Option Gain/Loss: Unopened
Average Daily Volume = 623 thousand
Entry on January -- at $---.--
Listed on January 10, 2014
Time Frame: 3 to 5 weeks, exit PRIOR to Q4 earnings
New Positions: Yes, see below

Company Description

Why We Like It:
CPHD is part of the technology sector but after you hear what they do the company sounds like they belong in the biotech industry. The company's marketing material describes themselves as "Based in Sunnyvale, Calif., Cepheid (CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer."

The stock struggled over the 2014 summer. Earnings in July came in two cents ahead of expectations. Yet management lowered their guidance. The stock collapsed. Now it looks like the company is seeing an earnings turnaround. Their most recent report was October 16th. Wall Street estimates were pretty wide ranging from breakeven ($0.00) to a loss of -16 cents. CPHD reported a loss of -6 cents. Yet revenues were up +15% to $115.2 million, which was above expectations. Gross margins improved as well with a jump from 49% to 52%. More importantly management raised their guidance for the rest of 2014. That fueled a nice rally in shares.

The company seems to be on a roll with a number of positive announcements. In just the last few weeks CPHD has announced European approval of Xpert HIV-1 Viral Load, which is a test to measure the active amount of HIV in a patient's blood. This is significant since nearly 35 million people globally are living with HIV/AIDS. The U.S. FDA recently approved CPHD's test to detect the presence of highly contagious Noroviruses of the genogroup 1 and genogroup II. This is significant since estimates suggest 267 million people are affected by a norovirus ever year and 200,000 people die annually. The FDA also issued an approval for a test to detect the presense of Flu A, Flu B, and the respiratory syncytial virus in a patient. CPHD said they also received a grant to work on an Ebola detection test that can be used on a person's saliva or blood.

Shares displayed relative strength on Friday with a +2.3% gain. The stock is challenging resistance in the $55-56 zone and on the verge of breaking out to new record highs. If CPHD does break out it could see some short covering. The most recent data listed short interest at 13% of the relatively small 69.4 million share float.

The November 28th intraday high was $56.47. More aggressive traders may want to jump in on a rally past $56.00. We are suggesting a trigger to buy calls at $56.55. Please note this could be a short-term trade. It looks like CPHD might report earnings at the very end of January and we will most likely exit prior to the announcement.

Trigger @ $56.55

- Suggested Positions -

Buy the MAR $55 CALL (CPHD150320C55) current ask $4.20

Option Format: symbol-year-month-day-call-strike

Daily Chart:

Weekly Chart:


Zebra Technology - ZBRA - close: 80.54 change: +1.16

Stop Loss: 78.75
Target(s): To Be Determined
Current Option Gain/Loss: Unopened
Average Daily Volume = 494 thousand
Entry on January -- at $---.--
Listed on January 10, 2014
Time Frame: Exit prior to earnings in February
New Positions: Yes, see below

Company Description

Why We Like It:
ZBRA is considered part of the industrial goods sector but they sound more like a technology company. The company website describes them as "Zebra Technologies is a global leader in enterprise asset intelligence, designing and marketing specialty printers, mobile computing, data capture, radio frequency identification products and real-time locating systems. Incorporated in 1969, the company has over 7,000 employees worldwide and provides visibility into valued assets, transactions and people."

Their goods are used by 90% of the Fortune 500 companies. They have almost no debt. Last year they spent almost $3.5 billion buying Motorola Solutions (symbol was MSI). ZBRA's CEO believes that the MSI acquisition will help them capitalize on three big trends: mobility, the Internet of things, and cloud computing.

In February 2014 ZBRA raised their earnings guidance. They did it again two months later in April. Their most recent earnings report was above expectations. ZBRA announced record revenues with sales up +19% in Middle East and Africa, +16% in North America, +11% in Latin America, and +9% in Asia Pacific.

Technically the stock has been stair-stepping higher with a bullish trend of higher lows and higher highs. This past week ZBRA displayed relative strength and broke out to new multi-month highs. The point & figure chart is bullish with a $92.00 target.

Tonight we are suggesting a trigger to buy calls at $80.85. We will plan on exiting positions before ZBRA reports earnings in mid February.

Trigger @ $80.85

- Suggested Positions -

Buy the FEB $85 CALL (ZBRA150220C85) current ask $1.65

Option Format: symbol-year-month-day-call-strike

Daily Chart:

Weekly Chart: